-
Publication Venue For
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
2022
-
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer..
82:858-866.
2022
-
Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis..
82:107-119.
2022
-
Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort..
81:1002-1008.
2021
-
The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer..
81:618-628.
2021
-
Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI..
81:521-529.
2021
-
Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population..
81:390-397.
2021
-
Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy..
80:1244-1252.
2020
-
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer..
79:1752-1761.
2019
-
The role of WNT10B in normal prostate gland development and prostate cancer..
79:1692-1704.
2019
-
E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer..
79:1226-1237.
2019
-
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer..
79:1106-1116.
2019
-
DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations..
79:657-666.
2019
-
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer..
79:604-613.
2019
-
HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer..
79:414-424.
2019
-
SRRM4 gene expression correlates with neuroendocrine prostate cancer..
79:96-104.
2019
-
Germline mutations in PPFIBP2 are associated with lethal prostate cancer..
78:1222-1228.
2018
-
A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer..
78:607-615.
2018
-
Rare germline mutations in African American men diagnosed with early-onset prostate cancer..
78:321-326.
2018
-
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer..
78:266-277.
2018
-
Genetic factors influencing prostate cancer risk in Norwegian men..
78:186-192.
2018
-
Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients..
78:17-24.
2018
-
The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?.
77:824-828.
2017
-
Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model..
77:446-457.
2017
-
Is PSA related to serum cholesterol and does the relationship differ between black and white men?.
75:1877-1885.
2015
-
A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate..
75:1447-1453.
2015
-
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America..
75:836-844.
2015
-
Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer..
75:616-627.
2015
-
Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes..
75:463-473.
2015
-
Carbohydrate intake, glycemic index and prostate cancer risk..
75:430-439.
2015
-
Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats..
75:381-389.
2015
-
Patient preferences for treatments to delay bone metastases..
74:1488-1497.
2014
-
Mutational landscape of candidate genes in familial prostate cancer..
74:1371-1378.
2014
-
Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer..
74:983-990.
2014
-
Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines..
73:1378-1390.
2013
-
Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways..
73:754-762.
2013
-
The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model..
73:449-454.
2013
-
Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database..
73:409-417.
2013
-
PDEF in prostate cancer..
72:592-596.
2012
-
Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG..
72:410-426.
2012
-
Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences..
72:173-180.
2012
-
Early onset prostate cancer has a significant genetic component..
72:147-156.
2012
-
Emerging treatment options for patients with castration-resistant prostate cancer..
72:338-349.
2012
-
PC3 is a cell line characteristic of prostatic small cell carcinoma..
71:1668-1679.
2011
-
Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study..
71:225-231.
2011
-
A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors..
70:1379-1387.
2010
-
Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses..
70:735-744.
2010
-
Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men..
69:956-960.
2009
-
Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer..
69:787-798.
2009
-
Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23..
69:385-391.
2009
-
Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy..
68:1380-1386.
2008
-
ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cells..
68:1273-1282.
2008
-
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
2017